Projects per year
Abstract
α-Methylacyl-CoA racemase (AMACR; P504S) catalyses a key step in the degradation of branched-chain fatty acids and is important for the pharmacological activation of Ibuprofen and related drugs. Levels of the enzyme are increased in prostate and other cancers, and it is a drug target. Development of AMACR as a drug target is hampered by lack of a convenient assay. AMACR irreversibly catalyses the elimination of HF from 3-fluoro-2-methylacyl-CoA substrates, and this reaction was investigated for use as an assay. Several known inhibitors and alternative substrates reduced substrate conversion by AMACR, as determined by 1H NMR. The greatest reduction of activity was observed for known potent inhibitors. A series of novel acyl-CoA esters with aromatic side chains were synthesised for testing as chromophoric substrates. These acyl-CoA esters were converted to unsaturated products by AMACR, but their use was limited by non-enzymatic elimination. Fluoride sensors were also investigated as a method of quantifying released fluoride and thus AMACR activity. These sensors generally suffered from high background signal and lacked reproducibility under the assay conditions. In summary, the elimination reaction can be used to characterise inhibitors, but it was not possible to develop a convenient colorimetric or fluorescent assay using 3-fluoro-2-methylacyl-CoA substrates.
Original language | English |
---|---|
Pages (from-to) | 612-622 |
Journal | Organic and Biomolecular Chemistry |
Volume | 14 |
Issue number | 2 |
Early online date | 27 Oct 2015 |
DOIs | |
Publication status | Published - Jan 2016 |
Keywords
- AMACR, prostate cancer, fluoride, fluorescent sensor
Fingerprint
Dive into the research topics of 'A study on the AMACR catalysed elimination reaction and its application to inhibitor testing'. Together they form a unique fingerprint.Projects
- 2 Finished
-
AMACR Targeted Drugs for Treating Advance Prostate Cancer
Lloyd, M. (PI), James, T. (CoI), Jevglevskis, M. (CoI), Nathubhai, A. (CoI), Threadgill, M. (CoI) & Woodman, T. (CoI)
1/02/15 → 30/07/18
Project: UK charity
-
Targeting AMACR to Treat Castrate Resistant Prostate Cancer
Lloyd, M. (PI) & Woodman, T. (CoI)
5/10/11 → 31/01/15
Project: UK charity
Profiles
Equipment
-
Avance III 500 MHz Nuclear Magnetic Resonance (NMR) Spectrometer (9West)
Material and Chemical Characterisation (MC2)Facility/equipment: Equipment
-
MC2-Bioimaging and cell analysis
Material and Chemical Characterisation (MC2)Facility/equipment: Technology type
-
MC2- Nuclear Magnetic Resonance (NMR)
Material and Chemical Characterisation (MC2)Facility/equipment: Technology type